Evidence map›Paper›PMID 37682116›Full record

ArticleHead & neck2023

Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy.

Meytal Guller, Dylan J Cooper, Hosam Alkhatib, Aditya Suru, Angelo Blancaflor, Christopher A Maroun, Tristan Tham, Hailey Allen, Eden Mazzara, Jerin Thomas and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Meytal GullerDepartment of Otolaryngology - Head and Neck Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Dylan J CooperDepartment of Otolaryngology - Head and Neck Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.ORCID 0000-0001-8511-8371
Hosam AlkhatibDepartment of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
Aditya SuruDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
Angelo BlancaflorDepartment of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
Christopher A MarounBloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.
Tristan ThamDepartment of Otolaryngology - Head and Neck Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.ORCID 0000-0002-5928-762X
Hailey AllenBloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.
Eden MazzaraDepartment of Otolaryngology - Head and Neck Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Jerin ThomasDepartment of Otolaryngology - Head and Neck Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Neha AminBloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.ORCID 0000-0001-7026-8887
Evan WuDepartment of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
David W EiseleDepartment of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
Carole FakhryDepartment of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
Drew PardollBloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.
Tanguy Y SeiwertBloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.
Gangcai ZhuBloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland, USA.
Rajarsi MandalDepartment of Otolaryngology - Head and Neck Surgery, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
Bloomberg (United States) · USJohns Hopkins University · USFeinstein Institute for Medical Research · USHofstra University · US

Funding

RESEARCH TRAINING IN OTOLARYNGOLOGYT32DC000027 · NIDCD · JOHNS HOPKINS UNIVERSITY · PI CAREY, JOHN PATRICK · 1989 to 2023
$5.5M
NIDCD NIH HHS T32 DC000027
6 · The paper itself

Abstract

objectivesTo explore the impact of pre-existing comorbidities on immunotherapy response, overall and progression-free survival, and immune-related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated with immunotherapy. PATIENTS AND

methodsNinety-three patients treated with immunotherapy were identified and stratified into comorbidity absent or present (CCI < 1 and CCI ≥ 1, respectively) cohorts, and clinical outcomes were compared between these two groups.

resultsPatients with no comorbidities had longer overall survival (aHR = 2.74, 95% CI [1.18, 6.40], p = 0.02) and progression-free survival (aHR = 2.07, 95% CI [1.03, 4.16], p = 0.04) and a higher tumor response rate (32% in CCI < 1 vs. 14% in CC ≥ 1, p = 0.05). Risk for irAEs was higher in the comorbidity absent group (p = 0.05).

conclusionComorbidity should be considered as a significant prognostic factor in clinical decision-making for patients with advanced HNC undergoing immunotherapy.

Indexed as

Head and Neck NeoplasmsComorbidityHumansImmunotherapyPrognosisProgression-Free SurvivalRetrospective Studiesadvanced head and neck cancerCharlson comorbidity indexcomorbiditiescomorbidityimmunotherapy

Identifiers

PMID37682116
PMCPMC10634321
OpenAlexW4386529503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.